Breaking News Instant updates and real-time market news.

AGN

Allergan

$173.01

-2.84 (-1.62%)

, NVS

Novartis

$80.75

-0.14 (-0.17%)

11:41
07/19/18
07/19
11:41
07/19/18
11:41

Allergan wet AMD data exceed 'unofficial benchmark,' says Wells Fargo

The released efficacy data from Allergan's (AGN) two Phase III trials of its anti-VEGF treatment abicipar in wet age-related macular degeneration looks to have exceeded the "unofficial benchmark set by potential extended-duration competitors," Novartis' (NVS) brolucizumab and Regeneron's (REGN) Eylea, Wells Fargo analyst David Maris tells investors in a research note. The analyst forecasts $125M in sales for abicipar in its first year on the market in 2020 and estimates it will grow to $500M in 2022. Maris keeps an Outperform rating on Allergan with a $240 price target.

AGN

Allergan

$173.01

-2.84 (-1.62%)

NVS

Novartis

$80.75

-0.14 (-0.17%)

REGN

Regeneron

$366.46

0.57 (0.16%)

  • 19

    Jul

  • 26

    Jul

  • 11

    Aug

  • 20

    Oct

  • 28

    Oct

AGN Allergan
$173.01

-2.84 (-1.62%)

06/27/18
MAXM
06/27/18
INITIATION
Target $6
MAXM
Buy
VistaGen Therapeutics initiated with a Buy at Maxim
As reported earlier, Maxim analyst Caroline Palomeque initiated VistaGen Therapeutics (VTGN) with a Buy rating and a price target of $6 based on its lead drug candidate, AV-101, an oral antidepressant targeting modulation of the NMDA receptor which is an emerging new class of antidepressants. The analyst notes that while Johnson & Johnson (JNJ) and Allergan (AGN) have first mover advantage in the NMDA class, their respective intranasal and IV in-office administration differentiates AV-101 as an oral at-home alternative. Palomeque notes the company's is progressing with its clinical development, as AV-101 undergoes phase 2 studies in treatment resistant major depressive disorder and adjunctive therapy in frontline failed patients, with data expected in the second half of this year and first half of 2019 respectively.
07/12/18
CANT
07/12/18
INITIATION
Target $59
CANT
Overweight
Cantor puts $59 price target on 'undervalued' NASH play Galmed
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Galmed Pharmaceuticals (GLMD) with an Overweight rating and $59 price target. The stock closed yesterday down 45c to $10.55. The company is developing Aramchol, a novel, once-daily, oral therapy to treat liver diseases using fattyacid/bile-acid conjugates, Piros tells investors in a research note. The analyst believes that by Q4 of 2019, only three meaningful non-alcoholic steatohepatitis pivotal programs will be in development: Allergan's (AGN) cenicriviroc, Madrigal Pharmaceuticals' (MDGL) MGL-3196, and Galmed's Aramchol. Of the three drugs, Galmed's has the highest likelihood of achieving improvement on NASH resolution without worsening of fibrosis, and improvement in fibrosis score without worsening of NASH, Piros argues. He believes Galmed is undervalued relative to peers in the NASH space.
07/09/18
MZHO
07/09/18
NO CHANGE
Target $194
MZHO
Neutral
Allergan price target raised to $194 from $176 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Allergan to $194 after extending her model to 2025 to "assess the beneficial impact" of the company's pipeline. Her new price target reflects a long-term outlook but the analyst reiterates a Neutral rating on Allergan.
07/19/18
PIPR
07/19/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron overhang 'effectively lifted' after Allergan data, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that Allergan (AGN) and Molecular Partners disclosed data from two Phase 3 trials comparing the latest DARPin formulation to Lucentis in age-related macular degeneration, calling the data "decidedly a non-starter." While few Regeneron (REGN) investors have expressed concern to Raymond over looming DARPin data, any overhang that did exist due to worries about another potential Eylea competitor in the AMD space have "been effectively lifted" following the DARPin data, said the analyst. He remains a buyer of Regeneron shares and keeps an Overweight rating and $450 price target on the stock.
NVS Novartis
$80.75

-0.14 (-0.17%)

07/12/18
PIPR
07/12/18
NO CHANGE
Target $95
PIPR
Neutral
PTAB decision on Gilenya positive for Celgene, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond expects the market to react positively with respect to Celgene (CELG) shares, at least initially, following the Patent Trial and Appeal Board decision regarding ozanimod competitor Gilenya from Novartis (NVS). Yesterday, the PTAB issued a decision that upholds validity of Gilenya's dosing patent in response to inter partes review petitions from multiple generic filers, Raymond tells investors in a research note. While this decision will likely be appealed, it opens up the possibility for Gilenya intellectual property runway out to 2027, when the dosing patent expire, the analyst adds. Raymond believes that not having a generic S1P class at launch for ozanimod is positive for Celgene. However, without the removal of first dose monitoring, ozanimod is not likely to be differentiated enough to make a difference, the analyst says, citing physician feedback. He keeps a Neutral rating on Celgene with a $95 price target. The stock in early trading is up 2% to $84.92.
07/19/18
LEHM
07/19/18
UPGRADE
LEHM
Equal Weight
Novartis upgraded to Equal Weight from Underweight at Barclays
07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.
07/16/18
MSCO
07/16/18
INITIATION
Target $37
MSCO
Overweight
AvroBio initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz initiated AvroBio (AVRO) with an Overweight rating and $37 price target, noting that its a unique gene therapy company that has human clinical data for one of its programs at the time of its initial public offering. He points to Novartis' (NVS) recent acquisition of AveXis for $8.7B, or an 88% premium, as an illustration of the substantial interest in and valuation premium put into many names in the gene therapy space.
REGN Regeneron
$366.46

0.57 (0.16%)

07/02/18
PIPR
07/02/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron has 'substantial' opportunity for Q2 upside, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says that with Dupixent script trends indicated up almost 30% quarter-over-quarter, Regeneron's (REGN) opportunity for Q2 upside is "substantial." Further, Regeneron and Sanofi (SNY) over the weekend raised the list price by 3% for the drug's first ever price increase, Raymond tells investors in a research note. He thinks Dupixent remains well positioned to outperform expectations "this quarter and beyond." The analyst maintains an Overweight rating on Regeneron with a $450 price target.
07/02/18
RHCO
07/02/18
NO CHANGE
Target $344
RHCO
Hold
Regeneron raised U.S. price of Dupixent by 3%, says SunTrust
Regeneron Pharmaceuticals (REGN) increased the U.S. price of Dupixent by 3.0% from $2,846.16 to $2,941.54 per package, effective June 29, SunTrust analyst Yatin Suneja tells investors in a research note, citing a third-party source. Piper Jaffray also highlighted the 3% price increase. This is the first price increase for Dupixent taken by Regeneron and partner Sanofi (SNY) since the drug was launched in March of 2017, the analyst points out. Suneja believes Dupixent could be on its way to becoming a multi-billion dollar franchise given its "rapid progress" in atopic dermatitis, October FDA action date for asthma and multiple Phase III readouts planned for later this year. The price increase should contribute $14M in incremental sales in 2018, Suneja predicts. The analyst keeps a Hold rating on Regeneron with a $344 price target. This report corrects the launch date of Dupixent.
07/18/18
PIPR
07/18/18
NO CHANGE
Target $450
PIPR
Overweight
Piper maintains Overweight on Regeneron on tanezumab news
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) on news that tanezumab, Pfizer (PFE) and Eli Lilly's (LLY) anti-NGF antibody that is a competitor to Regeneron's fasinumab, successfully completed the first of several Phase 3 trials. Fasinumab remains an unmodeled opportunity, but the read-through from tanezumab is positive and the market for an effective, non-opioid chronic pain treatment is "massive," Raymond tells investors in a research note. The analyst points out that Regeneron and Teva (TEVA) still expect to report Phase 3 data starting later this year. Raymond keeps an Overweight rating on Regeneron with a $450 price target.

TODAY'S FREE FLY STORIES

03:35
05/22/19
05/22
03:35
05/22/19
03:35
General news
FX Action: USD-CAD etched out a 12-day low »

FX Action: USD-CAD etched…

03:05
05/22/19
05/22
03:05
05/22/19
03:05
General news
FX Update: The main currencies have been trading narrow ranges »

FX Update: The main…

02:10
05/22/19
05/22
02:10
05/22/19
02:10
General news
Asian Market Wrap: »

Asian Market Wrap:…

01:45
05/22/19
05/22
01:45
05/22/19
01:45
General news
Fed's Bullard says rate cut could become "attractive option »

Fed's Bullard says…

CVNA

Carvana

$66.99

-0.175 (-0.26%)

21:14
05/21/19
05/21
21:14
05/21/19
21:14
Syndicate
Carvana 4.2M share Secondary priced at $65.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 18

    Jun

  • 22

    May

INSM

Insmed

$26.37

-1.71 (-6.09%)

20:57
05/21/19
05/21
20:57
05/21/19
20:57
Syndicate
Insmed 9.62M share Secondary priced at $26.00 »

Morgan Stanley, SVB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 22

    May

LOW

Lowe's

$111.10

1.86 (1.70%)

, ADI

Analog Devices

$99.98

2.54 (2.61%)

20:25
05/21/19
05/21
20:25
05/21/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

LOW

Lowe's

$111.10

1.86 (1.70%)

ADI

Analog Devices

$99.98

2.54 (2.61%)

TGT

Target

$72.05

-0.05 (-0.07%)

VFC

VF Corp.

$92.13

1.43 (1.58%)

AAP

Advance Auto Parts

$161.08

2.42 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 29

    May

  • 31

    May

  • 06

    Jun

  • 12

    Jun

  • 18

    Jun

20:25
05/21/19
05/21
20:25
05/21/19
20:25
Conference/Events
CLSA Asian tech analysts to hold an analyst/industry conference call »

Asian Technology Analysts…

SPY

SPDR S&P 500 ETF Trust

$286.50

2.55 (0.90%)

, SPX

S&P 500

$0.00

(0.00%)

20:24
05/21/19
05/21
20:24
05/21/19
20:24
Periodicals
China ambassador to U.S. says Beijing ready to continue talks, Reuters reports »

China ambassador to the…

SPY

SPDR S&P 500 ETF Trust

$286.50

2.55 (0.90%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEO

NeoGenomics

$21.81

-1.38 (-5.95%)

20:12
05/21/19
05/21
20:12
05/21/19
20:12
Syndicate
NeoGenomics 7M share Secondary priced at $21.25 »

Morgan Stanley, SVB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 05

    Jun

  • 06

    Jun

  • 13

    Nov

  • 23

    May

BAM

Brookfield

$47.03

0.02 (0.04%)

, BX

Blackstone

$41.79

1.17 (2.88%)

19:29
05/21/19
05/21
19:29
05/21/19
19:29
Periodicals
Brookfield, Fortress among bidders for Anbang hotel portfolio, Bloomberg says »

Brookfield Asset…

BAM

Brookfield

$47.03

0.02 (0.04%)

BX

Blackstone

$41.79

1.17 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 08

    Aug

GOLD

Barrick Gold

$12.12

-0.07 (-0.57%)

19:18
05/21/19
05/21
19:18
05/21/19
19:18
Hot Stocks
Barrick says Acacia proposal reflects 'fair value' following Tanzania talks »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SE

Sea Limited

$25.38

-0.42 (-1.63%)

19:04
05/21/19
05/21
19:04
05/21/19
19:04
Hot Stocks
Sea Limited reports Q1 QAUs up 114.4% from last year »

Reports Q1 Quarterly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

SE

Sea Limited

$25.38

-0.42 (-1.63%)

19:02
05/21/19
05/21
19:02
05/21/19
19:02
Earnings
Sea Limited reports Q1 EPS (64c), consensus (68c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

SNE

Sony

$51.01

-1.195 (-2.29%)

18:48
05/21/19
05/21
18:48
05/21/19
18:48
Periodicals
Sony aims to bolster cash flow to better compete in chips, games, NAR says »

Sony is seeking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jun

OOMA

Ooma

$14.49

-0.45 (-3.01%)

, CVI

CVR Energy

$47.29

0.9 (1.94%)

18:47
05/21/19
05/21
18:47
05/21/19
18:47
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ooma…

OOMA

Ooma

$14.49

-0.45 (-3.01%)

CVI

CVR Energy

$47.29

0.9 (1.94%)

PVH

PVH Corp.

$108.53

2.5075 (2.37%)

PSTG

Pure Storage

$20.60

0.6 (3.00%)

JWN

Nordstrom

$37.88

0.42 (1.12%)

URBN

Urban Outfitters

$27.01

0.05 (0.19%)

TOL

Toll Brothers

$38.34

0.82 (2.19%)

ONCS

OncoSec

$3.95

0.149 (3.92%)

EKSO

Ekso Bionics

$1.84

-0.06 (-3.16%)

TOCA

Tocagen

$8.81

-0.18 (-2.00%)

LIQT

LiqTech

$9.29

-0.21 (-2.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 10

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 09

    Jul

  • 22

    May

  • 22

    May

  • 22

    May

TREX

Trex Company

$61.44

2.38 (4.03%)

18:45
05/21/19
05/21
18:45
05/21/19
18:45
Hot Stocks
Trex Company CEO: There is no demand issue »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CRMT

America's Car-Mart

$101.76

1.74 (1.74%)

18:34
05/21/19
05/21
18:34
05/21/19
18:34
Earnings
America's Car-Mart reports Q4 EPS $2.07, consensus $1.82 »

Reports Q4 revenue $177M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 30

    May

  • 13

    Nov

JCOM

j2 Global

$87.23

0.75 (0.87%)

18:25
05/21/19
05/21
18:25
05/21/19
18:25
Hot Stocks
j2 Global CFO sells 5.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 05

    Jun

NVS

Novartis

$82.38

0.36 (0.44%)

18:24
05/21/19
05/21
18:24
05/21/19
18:24
Hot Stocks
Novartis CEO: We are entering an exciting growth phase for the company »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 31

    May

EADSY

Airbus

$0.00

(0.00%)

18:20
05/21/19
05/21
18:20
05/21/19
18:20
Periodicals
Airbus in talks to find resolution to German arms export row, Reuters says »

Airbus CEO Guillaume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGRO

Adecogro

$6.50

0.07 (1.09%)

18:19
05/21/19
05/21
18:19
05/21/19
18:19
Earnings
Adecogro reports Q1 adjusted EBITDA $58.3M, down 5.9% from last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,149.14

10.81 (0.95%)

, GOOGL

Alphabet Class A

$1,154.26

8.98 (0.78%)

18:01
05/21/19
05/21
18:01
05/21/19
18:01
Hot Stocks
Google updates policy on abortion-related ads »

Google said in a post…

GOOG

Alphabet

$1,149.14

10.81 (0.95%)

GOOGL

Alphabet Class A

$1,154.26

8.98 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 27

    Oct

HAIN

Hain Celestial

$23.90

0.45 (1.92%)

17:50
05/21/19
05/21
17:50
05/21/19
17:50
Hot Stocks
Engaged Capital raises stake in Hain Celestial to 20.2% from 18.3% »

Engaged Capital raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

17:48
05/21/19
05/21
17:48
05/21/19
17:48
Hot Stocks
Nintendo to end 'Animal Crossing,' 'Fire Emblem' mobile game service in Belgium »

Nintendo announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jun

  • 11

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.